Skip to main content
Premium Trial:

Request an Annual Quote

Celera Splits Stock, Creates Tools with Neomorphic, Takes Stake in Chinese Co

Premium

R

OCKVILLE, Md.--Celera Genomics’ stock price continued its climb on news of a planned two-for-one split, along with the announcement that it and the Berkeley, Calif., genomics firm Neomorphic have developed a browser software application for accessing Celera’s genomic databases.

The browser has been designed to enable Celera and its customers to research the human and Drosophila genomes for medically relevant and commercially valuable genes in the context of a complete genome. The price of Celera’s stock closed more than $10 up at $226.375 on the day of the announcements, according to SunSpot, the Baltimore Sun’s online news service.

Separately, Celera has also taken over a 47.5 percent equity stake in Shanghai GeneCore BioTechnologies, a genomics service company, from Axys Pharmaceuticals. The Chinese company said it is involved in nucleotide synthesis, DNA sequencing, bioinformatics analysis, and mutation detection and has ongoing research collaborations with several Chinese government agencies and research institutes.

Filed under

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.